Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 13
Interpreting and Communicating ctDNA Results
The panel examines challenges in interpreting circulating tumor DNA results and their impact on clinical decision-making processes.
- How do you factor ctDNA into treatment selection and management?
- How do you integrate ctDNA with radiographic or pathologic correlates?
- Are there challenges associated with the interpretation of ctDNA to inform your clinical decision-making?
- What do we know about sensitivity of ctDNA with different sites of metastatic disease?
- Navigating positive results
- Navigating false negatives
- How do you describe these test results to patients?
- Do you have any practical insights to share for interpretating and presenting results?
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
